文献速递胸部肿瘤乳腺癌消化系统肿瘤

癌症临床试验参与者年龄差异的相关因素分析

Factors Associated With Age Disparities Among Cancer Clinical Trial Participants.
PubMed 文献 · JAMA Oncol · 2019-01-01

该研究基于ClinicalTrials.gov的302项针对乳腺癌、前列腺癌、结直肠癌或肺癌的多臂3期随机对照试验,共纳入262354名参与者。结果显示试验参与者中位年龄平均比人群疾病特异性中位年龄年轻6.49岁(95%CI,-7.17至-5.81岁;P<.001),且行业资助试验的年龄差异更大(平均差异-6.84岁 vs 非行业资助-4.72岁;P=.002),年龄差异随时间以每年-0.19年的速率扩大(95%CI,-0.37至-0.01年;P=.04)。

要点

  • 试验参与者中位年龄较人群疾病特异性中位年龄平均年轻6.49岁(95%CI,-7.17至-5.81岁;P<.001)。
  • 行业资助试验的年龄差异大于非行业资助试验(平均差异-6.84岁 vs -4.72岁;P=.002)。
  • 评估靶向系统性治疗的试验和肺癌试验中年龄差异更大;年龄差异随时间以每年-0.19年的速率扩大(95%CI,-0.37至-0.01年;P=.04)。

核心结论

  • 试验参与者与疾病发病人群之间的年龄差异普遍存在,且似乎随时间增加。
  • 行业资助的试验与试验参与者中更大的年龄不平衡相关。
  • 随着行业资助在癌症试验中作用增加,需要努力理解和解决年龄差异,以确保试验结果的普遍性以及试验准入的公平性。

研究设计与样本

  • 通过ClinicalTrials.gov识别3期临床肿瘤随机对照试验。
  • 纳入针对乳腺癌、前列腺癌、结直肠癌或肺癌(4个最常见癌症部位)患者的多臂治疗性随机对照试验。
  • 由两名人员独立进行试验筛选和参数识别,数据于2018年分析。
  • 共302项试验符合纳入标准,合计纳入262354名参与者;其中249项试验(82.5%)为行业资助。

主要发现

  • 所有试验中,试验参与者中位年龄平均比人群疾病特异性中位年龄年轻6.49岁(95%CI,-7.17至-5.81岁;P<.001)。
  • 行业资助试验的年龄差异大于非行业资助试验(平均差异-6.84岁 vs -4.72岁;P=.002)。
  • 基于体能状态或年龄截断值的入组标准限制与年龄差异相关;但行业资助试验并不比非行业资助试验更可能使用这些入组限制。
  • 评估靶向系统性治疗的试验和肺癌试验中年龄差异更大。
  • 线性回归模型显示试验与人群中位年龄之间的差距随时间以每年-0.19年的速率扩大(95%CI,-0.37至-0.01年;P=.04)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Seminal investigation 2 decades ago alerted the oncology community to age disparities in participation in cooperative group trials; less is known about whether these disparities persist in industry-funded research. OBJECTIVE: To characterize the age disparities among trial enrollees on randomized clinical trials (RCTs) of common cancers in clinical oncology and identify factors associated with wider age imbalances. DATA SOURCES: Phase 3 clinical oncology RCTs were identified through ClinicalTrials.gov. STUDY SELECTION: Multiarm RCTs assessing a therapeutic intervention for patients with breast, prostate, colorectal, or lung cancer (the 4 most common cancer disease sites) were included. DATA EXTRACTION AND SYNTHESIS: Trial data were extracted from ClinicalTrials.gov. Trial screening and parameter identification were independently performed by 2 individuals. Data were analyzed in 2018. MAIN OUTCOMES AND MEASURES: The difference in median age (DMA) between the trial participant median age and the population-based disease-site-specific median age was determined for each trial. RESULTS: Three hundred two trials met inclusion criteria. The trials collectively enrolled 262 354 participants; 249 trials (82.5%) were industry-funded. For all trials, the trial median age of trial participants was a mean of 6.49 years younger than the population median age (95% CI, -7.17 to -5.81 years; P < .001). Age disparities were heightened among industry-funded trials compared with non-industry-funded trials (mean DMA, -6.84 vs -4.72 years; P = .002). Enrollment criteria restrictions based on performance status or age cutoffs were associated with age disparities; however, industry-funded trials were not more likely to use these enrollment restrictions than non-industry-funded trials. Age disparities were also larger among trials that evaluated a targeted systemic therapy and among lung cancer trials. Linear regression modeling revealed a widening gap between trial and population median ages over time at a rate of -0.19 years annually (95% CI, -0.37 to -0.01 years; P = .04). CONCLUSIONS AND RELEVANCE: Age disparities between trial participants and the incident disease population are pervasive across trials and appear to be increasing over time. Industry sponsorship of trials is associated with heightened age imbalances among trial participants. With an increasing role of industry funding among cancer trials, efforts to understand and address age disparities are necessary to ensure generalizability of trial results as well as equity in trial access.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Ludmir EB, Mainwaring W, Lin TA, et al. Factors Associated With Age Disparities Among Cancer Clinical Trial Participants. JAMA Oncol. 2019. PMID: 31158272. doi:10.1001/jamaoncol.2019.2055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。